ORIC Launches Phase 3 Trial, Extends Cash Runway to 2H 2028 with $387.6M
ORIC sits 47% above its 52-week low of $7.23.
Summary
ORIC Pharmaceuticals initiated a global Phase 3 trial for rinzimetostat in prostate cancer and reported a cash runway into 2H 2028, with key clinical data readouts expected in the second half of 2026.
Key Events · Earnings and Guidance · ORIC
-
Phase 3 Trial Initiation
The Himalayas-1 global Phase 3 registrational trial for rinzimetostat in mCRPC is now underway, enrolling approximately 600 patients across 250 sites in 25 countries.
-
Bayer Collaboration
Bayer will supply darolutamide at no cost for the trial, while ORIC retains full global development and commercial rights to rinzimetostat.
-
Cash Runway Extended
With cash and investments of $387.6 million as of June 30, 2026, operations are funded into 2H 2028, beyond the anticipated primary endpoint readout from the first Phase 3 trial.
-
Financial Results
A Q2 2026 net loss of $41.5 million ($0.38 per share) was driven by R&D expenses of $36.3 million, reflecting increased investment in advancing rinzimetostat.
Analysis · ORIC · Life Sciences
Advancing its lead candidate rinzimetostat into a global Phase 3 registrational trial for prostate cancer marks a major de-risking event for this clinical-stage biotech. A collaboration with Bayer will supply darolutamide at no cost, while ORIC retains full commercial rights. The $387.6 million cash position provides a runway into the second half of 2028, well beyond the anticipated primary endpoint readout from the first Phase 3 trial, reducing near-term dilution risk. Although the Q2 net loss widened to $41.5 million on higher R&D spending, the cash cushion and upcoming catalysts—including enozertinib data at ESMO in October 2026—position the company for multiple value-creating milestones.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ORIC was trading at $10.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $7.23 to $14.93. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.